We’ve developed hundreds of medicines across all dosage forms. Along the way, we’ve earned our reputation as a trusted leader in highly complex medicines. Our pipeline centers on meeting unmet needs, filling drug shortages and opening access to the world’s most advanced and critical medicines.
As of November 2026, we have 54 ANDAs pending and 64 pipeline programs.
Data in the chart below as of November 2026. All trademarks listed below are the property of their respective owners.
Review our Biosimilars pipeline here: Biosimilars - Amneal Pharmaceuticals
Launch Date / Anticipated Launch Date
Launch Date / Anticipated Launch Date
Therapeutic Area - Hematology
Referenced Brand - Promacta®
Dosage Form - Tablet
Approval - Q1’26*
Launch - Q1’26
Therapeutic Area - Emergency/Critical Care
Referenced Brand - Adrenalin®
Dosage Form - SDV/MDV/PFS
Approval - Q4’25
Launch - Q1’26
Therapeutic Area - Hematology/Oncology
Referenced Brand - Revlimid®
Dosage Form - Capsule
Approval - Q1’25
Launch - Q1’26
Therapeutic Area - Neurology (narcolepsy)
Referenced Brand - Xyrem®
Dosage Form – Oral solution
Approval – Q3’25
Launch -– Q1’26
Therapeutic Area - Psychiatry
Referenced Brand - Risperdal Consta®
Dosage Form – Vial
Approval – Q3’25
Launch -– Q1’26
Therapeutic Area - Ophthalmology
Referenced Brand - Restasis®
Dosage Form - Ophthalmic
Approval - Q4’25*
Launch - Q1’26
Therapeutic Area - Respiratory
Referenced Brand - QVAR®
Dosage Form - Inhalation
Approval - Q4’25
Launch - Q1’26
Therapeutic Area - Diagnostic
Referenced Brand - Omnipaque®
Dosage Form - Vial
Approval - Q4’25
Launch - Q2’26
Launch Date / Anticipated Launch Date
Therapeutic Area - Ophthalmology
Referenced Brand - Lumigan®
Dosage Form - Ophthalmic
Approval - Q3’25
Launch - Q2’26
Therapeutic Area Respiratory
Referenced Brand - ProAir® HFA
Dosage Form - Inhalation
Approval - Q4’25
Launch - Q2’26
Therapeutic Area - Oncology
Referenced Brand - Romidepsin
Dosage Form - Vial
Approval - Q2’26*
Launch - Q2’26
Launch Date / Anticipated Launch Date
Therapeutic Area - Endocrinology/Oncology
Referenced Brand - Somatuline® Depot
Dosage Form - PFS
Approval - Q3’26
Launch - Q3’26
Launch Date / Anticipated Launch Date
Therapeutic Area - Emergency/Critical Care
Referenced Brand - Adrenalin®
Dosage Form - PFS
Approval - Q4’25*
Launch -– Q1’26#
Therapeutic Area – Critical Care
Referenced Brand - Neut®
Dosage Form – IV Bag
Approval – Q3’26*
Launch – Q3’26#
Therapeutic Area - Diagnostic
Referenced Brand - Omnipaque®
Dosage Form - Vial
Approval – Q2’26
Launch – Q4’26
Launch Date / Anticipated Launch Date
Therapeutic Area - Emergency/Critical Care
Referenced Brand - Adrenalin®
Dosage Form - PFS
Approval - Q2’27*
Launch -– Q2’27#
Therapeutic Area – Critical Care
Referenced Brand – Sodium Phosphate®
Dosage Form – Vial
Approval – Q4’26
Launch – 2027#
Launch Date / Anticipated Launch Date
Therapeutic Area - Gastroenterology
Referenced Brand - Xifaxan®
Dosage Form - Tablet
Approval - Q1’25
Launch - Undisclosed
Therapeutic Area - Oncology
Referenced Brand - Romidepsin
Dosage Form - Vial
Approval - Q2’26*
Launch - Q3’26*
Note: Selected new product launches listed. Additional opportunities not disclosed. All trademarks are the property of their respective owners. PFS = Prefilled Syringe; MDV = Multiple-dose vial; RTU = Ready-to-use; SDV = Single-dose vial; BLA = Biologics License Application.
* Not yet approved, estimated approval date
# Not yet launched, estimated launch date
Corporate
India